ONCSQ — OncoSec Medical Incorporated Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Brief: Oncosec Receives CE Mark Certification For Commercial Electroporation Device For Treatment Of Solid Tumors
Brief: Oncosec Announces Publication In Clinical Cancer Research Of Data Supporting The Therapeutic Potential Of Lead Product Candidate, Tavo™, In Triple Negative Breast Cancer
Brief: OncoSec Announces Approval Of $2.5 Million In NJEDA NOL Program Tax Benefits
OncoSec: Rises as dosing begins in COVID-19 vaccine candidate study
Brief: Oncosec Says First Subjects Dosed In Phase 1 Trial Of Corvax12
Brief: OncoSec Medical Announces Pricing Of $42.0 Million Public Offering Of Common Stock
Brief: OncoSec Medical Announces Proposed Public Offering Of Common Stock
Promote Tavo
Brief: Oncosec Announces First Patient Dosed In Phase 2 Trial Of Tavo Plus Opdivo As Neoadjuvant Therapy For Melanoma
Brief: Oncosec Medical Inc Says European Patent Office Has Issued Notices Of Intention To Grant For Two Patent Applications
Brief: Oncosec Announces Exclusive License Agreement For Cliniporator® Gene Electrotransfer Platform Developed By Igea Clinical Biophysics
Brief: Alpha Holdings, Inc Reports 6.76% Stake In Oncosec Medical As Of November 16
Brief: Oncosec Announces Positive Interim Data From KEYNOTE-695 Trial In Anti-PD-1 Checkpoint Refractory Metastatic Melanoma
Brief: Oncosec To Present Positive Interim Data From Keynote-695 Trial In Anti-Pd-1 Checkpoint Refractory Metastatic Melanoma At Sitc 2020
U.S. STOCKS ON THE MOVE-Tricida, Cancer Genetics, Penumbra Inc
U.S. STOCKS ON THE MOVE-Cancer Genetics, Tricida, Pinterest
Brief: OncoSec Reports FDA Approval To Begin Clinical Trial Of COVID-19 Vaccine Candidate
OncoSec: Jumps on FDA nod to start testing COVID-19 vaccine candidate
Brief: OncoSec Announces Issuance Of New U.S. Patent Expanding Coverage Of TAVO